¼¼°èÀÇ ÇÁ·ÎÅ׿À¹Í½º ½ÃÀå º¸°í¼ : ºÐ¼® À¯Çü, ±¸¼º ¿ä¼Ò À¯Çü, ±â¼ú, ÀÀ¿ë ºÐ¾ß, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)
Proteomics Market Report by Analysis Type, Component Type, Technology, Application, End-User (Clinical Diagnostic Laboratories, Research Organizations, and Others), and Region 2024-2032
¼¼°è ÇÁ·ÎÅ׿À¹Í½º ½ÃÀå ±Ô¸ð´Â 2023³â 363¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 1,262¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2024-2032³â°£ 14.4%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.
ÇÁ·ÎÅ׿À¹Í½º(Proteomics)´Â ÇÁ·ÎÅ׿È, ±× ±¸Á¶¿Í »ý¸®Àû ±â´ÉÀ» ´ë±Ô¸ð·Î ¿¬±¸ÇÏ´Â °ÍÀ¸·Î, 1994³â ¸¶Å© ÀªÅ²½º(Mark Wilkins)´Â À¯Àüü¿¡¼ ¹ø¿ªµÇ´Â ´Ü¹éÁúÀ» ÇÁ·ÎÅ׿ÈÀ̶ó°í ºÎ¸£¸ç »ý¹°Ã¼ ³»¿¡¼ ÇÕ¼ºµÇ´Â Àüü ´Ü¹éÁúÀ» óÀ½À¸·Î Á¤ÀÇÇß½À´Ï´Ù. ÇÁ·ÎÅ׿ȿ¡´Â ±âÁ¸ ´Ü¹éÁúÀÌ ´Ù¾çÇÑ Á¶°Ç¿¡ ³ëÃâµÇ¾úÀ» ¶§ ÀϾ´Â º¯ÇüÀ̳ª º¯È°¡ Æ÷ÇԵ˴ϴÙ. ÇÁ·ÎÅ׿À¹Í½º´Â Áø´Ü ¸¶Ä¿ÀÇ °ËÃâ, ¼¼Æ÷ ³» º´¿ø±ÕÀÇ ÀÌÇØ, ´Ù¾çÇÑ Áúº´ÀÇ ´Ü¹éÁú °æ·Î ÇØ¼®°ú ÇÔ²² ´Ü¹éÁúÀÇ Á¤·®È ¹× µ¿Á¤À» À§ÇØ ´Ù¾çÇÑ ±â¼úÀ» Àû¿ëÇÕ´Ï´Ù. ÇÁ·ÎÅ׿À¹Í½º´Â ¶ÇÇÑ ´Ü¹éÁúÀÇ »ý»ê ¼Óµµ¿Í »óÈ£ ÀÛ¿ë ÆÐÅÏÀ» Æò°¡ÇÏ¿© ½Å¾à °³¹ß ¹× ¸ÂÃãÇü ÀǾàǰ °³¹ß¿¡ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.
½Å¾à °³¹ß ¹× »ý¸í°øÇÐ ¿¬±¸ °³¹ß Áõ°¡¿Í ÇÔ²² °³ÀÎ ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÇÁ·ÎÅ׿À¹Í½º ½Ã½ºÅÛÀº ÀǾàǰÀÇ ÈÇÐÀû ÇÕ¼º ¹× »ý¹°ÇÐÀû Å×½ºÆ®¿¡ ÇÊ¿äÇÑ ½Ã°£, ºñ¿ë ¹× ÀÚ¿øÀ» ÁÙ¿© ½Å¾à °³¹ß ÇÁ·Î¼¼½º¸¦ °£¼ÒÈÇÕ´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¸¶Ä¿ ½Äº° ¹× Áú·® ºÐ¼® ±â¹Ý ÇÁ·ÎÅ׿À¹Í½º °ü·Ã ±âȸ´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´Ü¹éÁú ±â¼úÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®¿¡ ´ëÇÑ ±â¼ú º¸±ÞÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú¿¡´Â Àü±âºÐ¹« ÀÌ¿ÂÈ-¾×ü Å©·Î¸¶Åä±×·¡ÇÇ-Áú·® ºÐ¼®(ESI-LC-MS), Ç¥¸é ÇöóÁ °ø¸í, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, ´Ü¹éÁú ºÐȹ ½Ã½ºÅÛ, X-¼± °áÁ¤ ±¸Á¶ ºÐ¼® µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ´Ü¹éÁúÀÇ Ã¶ÀúÇÑ Á¤·®Àû, Á¤¼ºÀû ºÐ¼®ÀÌ °¡´ÉÇØÁ® ¾Ï Ä¡·á¹ý ¹× Ä¡·á¹ýÀ» ½Äº°ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D)¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Á¤Ã¥ µî ´Ù¸¥ ¿äÀε鵵 ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®µé
- ÇÁ·ÎÅ׿À¹Í½º ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â?
- 2024-2032³â ¼¼°è ÇÁ·ÎÅ׿À¹Í½º ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
- ¼¼°è ÇÁ·ÎÅ׿À¹Í½º ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº?
- Äڷγª19°¡ ¼¼°è ÇÁ·ÎÅ׿À¹Í½º ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
- ¼¼°è ÇÁ·ÎÅ׿À¹Í½º ½ÃÀåÀÇ ±â¼úº° ºÐ¼®Àº?
- ¼¼°è ÇÁ·ÎÅ׿À¹Í½º ½ÃÀåÀÇ ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®Àº?
- ÇÁ·ÎÅ׿À¹Í½º ½ÃÀåÀÇ ¼¼°è ÁÖ¿ä Áö¿ªÀº?
- ¼¼°è ÇÁ·ÎÅ׿À¹Í½º ½ÃÀåÀÇ ÁÖ¿ä ÁøÃâ ±â¾÷Àº?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»ç ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼·Ð
Á¦5Àå ¼¼°èÀÇ ÇÁ·ÎÅ׿À¹Í½º ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ºÐ¼®
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ºÐ¼® : ºÐ¼® À¯Çüº°
- ±¸Á¶ ÇÁ·ÎÅ׿À¹Í½º
- ±â´É ÇÁ·ÎÅ׿À¹Í½º
- ´Ü¹éÁú ¹ßÇö ÇÁ·ÎÅ׿À¹Í½º
Á¦7Àå ½ÃÀå ºÐ¼® : ÄÄÆ÷³ÍÆ® À¯Çüº°
- ÄÚ¾î ÇÁ·ÎÅ׿À¹Í½º ¼ºñ½º
- ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼ÒÇÁÆ®¿þ¾î ¹× °ü·Ã ¼ºñ½º
Á¦8Àå ½ÃÀå ºÐ¼® : ±â¼úº°
- ºÐ±¤¹ý
- Å©·Î¸¶Åä±×·¡ÇÇ
- Àü±â¿µµ¿
- ´Ü¹éÁú ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
- X¼± °áÁ¤ ±¸Á¶ ºÐ¼®
- Ç¥¸é ÇÁ¶óÁî¸ó °ø¸í
- ±âŸ
Á¦9Àå ½ÃÀå ºÐ¼® : ¿ëµµº°
- ´Ü¹éÁú ¹ßÇö ÇÁ·ÎÆÄÀϸµ
- ÇÁ·ÎÅ×¿È ±¤¾÷
- ¹ø¿ªÈÄ º¯Çü
Á¦10Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
- ÀÓ»ó Áø´Ü½ÇÇè½Ç
- ¿¬±¸±â°ü(Drug Discovery)
- ±âŸ
Á¦11Àå ½ÃÀå ºÐ¼® : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ½ÃÀå µ¿Çâ
- ½ÃÀå ºÐ¼® : ±¹°¡º°
- ½ÃÀå ¿¹Ãø
Á¦12Àå SWOT ºÐ¼®
Á¦13Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦14Àå PorterÀÇ Five Forces ºÐ¼®
- °³¿ä
- ¹ÙÀ̾îÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀï Á¤µµ
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦15Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ °³¿ä
- Agilent Technologies Inc.
- Bio-RAD Laboratories Inc.
- Bruker Corporation
- Creative Proteomics
- Danaher Corporation
- GE Healthcare Inc.
- Horiba Ltd.
- Luminex Corporation
- Merck Group
- Perkinelmer Inc.
- Promega Corporation
- Thermo Fisher Scientific Inc.
- Waters Corporation
LSH
The global proteomics market size reached US$ 36.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 126.2 Billion by 2032, exhibiting a growth rate (CAGR) of 14.4% during 2024-2032.
Proteomics refers to the study of proteomes, their structure and physiological functions on a large-scale. In 1994, Mark Wilkins first coined the term proteome for the proteins that are translated from genome, to denote the whole set of proteins synthesized within a living organism. It encompasses the modifications and alterations that take place in the existing protein when it is exposed to varying conditions. Proteomics applies various technologies for the quantification and identification of proteins, along with the detection of diagnostic markers, understanding of pathogens in cells and interpretation of protein pathways in different diseases. It also evaluates the rate of protein production and the interaction patterns of proteins due to which it finds extensive applicability in drug discovery and the development of personalized medications.
The growing preference for personalized drugs, along with increasing research and development in drug discovery and biotechnology, is the key factor driving the growth of the market. Proteomic systems reduce the time, cost and resources needed for the chemical synthesis and biological testing of drugs and simplify the process of drug discovery. Furthermore, opportunities related to biomarker identification and mass spectrometry-based proteomics are favoring the market growth further. Additionally, the market is driven by increasing technological penetration in the comprehensive analysis of protein techniques. These techniques include Electrospray Ionization-Liquid Chromatography-Mass Spectrometry (ESI-LC-MS), surface plasma resonance, microarray, protein fractionation systems and X-ray crystallography. These advancements enable a thorough quantitative and qualitative analysis of proteins and identification of cancer therapies and treatments. Other factors, such as favorable government policies for extensive research and development (R&D) are also augmenting the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global proteomics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on analysis type, component type, technology, application and end-user.
Breakup by Analysis Type:
Structural Proteomics
Functional Proteomics
Protein Expression Proteomics
Breakup by Component Type:
Core Proteomics Services
Bioinformatics Software and Related Services
Breakup by Technology:
Spectroscopy
Chromatography
Electrophoresis
Protein Microarrays
X-Ray Crystallography
Surface Plasmon Resonance
Others
Breakup by Application:
Protein Expression Profiling
Proteome Mining
Post-translational Modifications
Breakup by End-User:
Clinical Diagnostic Laboratories
Research Organizations (Drug Discovery)
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.
Key Questions Answered in This Report
- 1. How big is the global proteomics market?
- 2. What is the expected growth rate of the global proteomics market during 2024-2032?
- 3. What are the key factors driving the global proteomics market?
- 4. What has been the impact of COVID-19 on the global proteomics market?
- 5. What is the breakup of the global proteomics market based on the technology?
- 6. What is the breakup of the global proteomics market based on the end-user?
- 7. What are the key regions in the global proteomics market?
- 8. Who are the key players/companies in the global proteomics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Proteomics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Analysis Type
- 6.1 Structural Proteomics
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Functional Proteomics
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Protein Expression Proteomics
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Component Type
- 7.1 Core Proteomics Services
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Bioinformatics Software and Related Services
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Technology
- 8.1 Spectroscopy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Chromatography
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Electrophoresis
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Protein Microarrays
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 X-Ray Crystallography
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Surface Plasmon Resonance
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
- 8.7 Others
- 8.7.1 Market Trends
- 8.7.2 Market Forecast
9 Market Breakup by Application
- 9.1 Protein Expression Profiling
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Proteome Mining
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Post-translational Modifications
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by End-User
- 10.1 Clinical Diagnostic Laboratories
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Research Organizations (Drug Discovery)
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Others
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
- 11.2 Asia Pacific
- 11.2.1 China
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
- 11.2.2 Japan
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
- 11.2.3 India
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
- 11.2.4 South Korea
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
- 11.2.5 Australia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
- 11.3 Europe
- 11.3.1 Germany
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
- 11.3.2 France
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
- 11.3.4 Italy
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
- 11.3.5 Spain
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
- 11.3.6 Russia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
12 SWOT Analysis
- 12.1 Overview
- 12.2 Strengths
- 12.3 Weaknesses
- 12.4 Opportunities
- 12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Agilent Technologies Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Bio-RAD Laboratories Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Bruker Corporation
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Creative Proteomics
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Danaher Corporation
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 GE Healthcare Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 Horiba Ltd.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.8 Luminex Corporation
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Merck Group
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Perkinelmer Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Promega Corporation
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.12 Thermo Fisher Scientific Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.13 Waters Corporation
- 15.3.13.1 Company Overview
- 15.3.13.2 Product Portfolio
- 15.3.13.3 Financials
- 15.3.13.4 SWOT Analysis